Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We present the CLARITY trial that combined ibrutinib with venetoclax to eradicate detectable CLL with the intention of stopping therapy. PATIENTS AND METHODS: CLARITY is a phase II trial that combined ibrutinib with venetoclax in patients with relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy. Key secondary end points were response by International Workshop on CLL criteria, safety, and progression-free and overall survival. RESULTS: In 53 patients after 12 months of ibrutinib plus venetoclax, MRD negativity (fewer than one CLL cell in 10,000 leukocytes) was achieved in the blood of 28 (53%) and the marrow of 19 (36%). Forty-seven patients (89%) responded, and 27 (51%) achieved a complete remission. After a median follow-up of 21.1 months, one patient progressed, and all patients were alive. A single case of biochemical tumor lysis syndrome was observed. Other adverse effects were mild and/or manageable and most commonly were neutropenia or GI events. CONCLUSION: The combination of ibrutinib plus venetoclax was well tolerated in patients with relapsed or refractory CLL. There was a high rate of MRD eradication that led to the cessation of therapy in some patients. The progression-free and overall survival rates are encouraging for relapsed and refractory CLL.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.19.00894
Authors: Peter Hillmen, Andy C. Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J. Yates, Rebecca Bishop, Rebecca Boucher, Donald MacDonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P. Fox, Francesco Forconi, Talha Munir
Institutions: University of Leeds, St James's University Hospital, Cancer Research UK Clinical Trials Unit, Imperial College Healthcare NHS Trust, Cardiff and Vale University Health Board, University Hospital of Wales, Beatson West of Scotland Cancer Centre, Oxford University Hospitals NHS Trust, University of Liverpool, Barts Health NHS Trust, King's College London, King's College Hospital NHS Foundation Trust, The Christie Hospital, Nottingham University Hospitals NHS Trust, Cancer Research UK, University Hospital Southampton NHS Foundation Trust, National Institute for Health and Care Research, NIHR CRUK Experimental Cancer Medicine Centre, University of Southampton
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: G7681213648, G8821896511
OpenAlex ID: W2962038803
